ImmunityBio announces FDA approval for Anktiva plus BCG treatment

ImmunityBio announced that the FDA has approved Anktiva plus Bacillus Calmette-Guerin, or BCG, for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer, or NMIBC, with carcinoma in situ, or CIS, with or without papillary tumors.